All-trans retinoic acid (ATRA), a derivative of vitamin A, possesses a captivating duality. In the realm of medicine, it’s a potent weapon against acute promyelocytic leukemia (APL), a type of blood cancer. But step into the domain of cosmetics, and ATRA transforms into a radiant hero, combating acne and promoting youthful skin. This remarkable versatility has propelled ATRA to the forefront of global markets, attracting a diverse range of buyers seeking its unique properties. Top Global Buyers of ATRA: Pharmaceutical companies: Giants like Roche and Novartis utilize ATRA as the mainstay treatment for APL, driving significant demand for bulk quantities. Hospitals and cancer centers: These institutions directly administer ATRA to…